DOCSLIB.ORG

Interactions with PBC Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

www.hep-druginteractions.org Interactions with PBC Agents Charts created August 2019. Full information available at www.hep-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Acid Acid Anaesthetics & Muscle Relaxants Antibacterials (continued) Antidepressants Bupivacaine Dapsone Agomelatine Cisatracurium Delamanid Amitriptyline Isoflurane Ertapenem Bupropion Ketamine Erythromycin Citalopram Nitrous oxide Ethambutol Clomipramine Propofol Flucloxacillin Desipramine Thiopental Gentamicin Desvenlafaxine Tizanidine Imipenem Dosulepin Analgesics Isoniazid Doxepin Aceclofenac Levofloxacin Duloxetine Alfentanil Linezolid Escitalopram Aspirin Lymecycline Fluoxetine Buprenorphine Meropenem Fluvoxamine Celecoxib Imipramine Methenamine Codeine distribution. for Lithium Metronidazole Dexketoprofen Maprotiline Moxifloxacin Dextropropoxyphene Mianserin Nitrofurantoin Diamorphine Milnacipran Diclofenac Norfloxacin Mirtazapine Diflunisal Ofloxacin Moclobemide Dihydrocodeine Penicillin V Nefazodone Etoricoxib Piperacillin Nortriptyline Fentanyl Pivmecillinam Paroxetine Flurbiprofen Pyrazinamide Sertraline Hydrocodone distribution. for only. Not use ersonal Rifabutin Tianeptine Hydromorphone Rifampicin Trazodone Ibuprofen Rifapentine Trimipramine Indometacin Rifaximin Venlafaxine Ketoprofen Spectinomycin Vortioxetine Mefenamic acid Streptomycin Meloxicam Antidiabetics Sulfadiazine Metamizole (Dipyrone) Acarbose Tazobactam Methadone Albiglutide Morphine Telithromycin Alogliptin Temocillin Naproxen Canagliflozin Oxycodone Tetracyclines Not only. use For personal for distribution. Dapagliflozin Paracetamol Ticarcillin Dulaglutide Pethidine (Meperidine) Trimethoprim/Sulfamethoxazole Empagliflozin Piroxicam Troleandomycin Exenatide Tapentadol Vancomycin Glibenclamide (Glyburide) Tramadol Anticoagulant, Antiplatelet & Fibrinolytic Gliclazide Anthelmintics Acenocoumarol Glimepiride Albendazole Anagrelide Glipizide nal use only. Not for distribution. For p for distribution. Not only. use nal Ivermectin Apixaban Insulin Oxamniquine Clopidogrel Linagliptin Praziquantel Dabigatran Liraglutide Pyrantel r perso Dalteparin Lixisenatide Danaparoid Antiarrhythmics Metformin Dipyridamole Amiodarone Nateglinide Edoxaban Bepridil Pioglitazone Eltrombopag Digoxin Repaglinide Disopyramide Enoxaparin Rosiglitazone Dofetilide Fluindione Saxagliptin Dronedarone Fondaparinux Flecainide Heparin Sitagliptin Lidocaine (Lignocaine) Phenprocoumon Tolbutamide Mexiletine Prasugrel Vildagliptin Propafenone Rivaroxaban Antifungals Quinidine Streptokinase Amphotericin B Vernakalant Ticagrelor Anidulafungin Antibacterials Ticlodipine Caspofungin Amikacin Tinazaparin Fluconazole Amoxicillin Warfarin Flucytosine Ampicillin Anticonvulsants Griseofulvin Azithromycin Carbamazepine Isavuconazole Aztreonam Clonazepam Itraconazole Bedaquiline Eslicarbazepine Ketoconazole Benzylpenicillin Ethosuximide For personal use only. Not for distribution. Fo for distribution. Not only. use For personal For personal use only. Not for distribution. For personal use only. Not Not only. use For personal for distribution. only. Not use For personal Miconazole Gabapentin Capreomycin Nystatin Lacosamide Cefaclor Posaconazole Cefadroxil Lamotrigine Terbinafine Cefalexin Levetiracetam Voriconazole Cefazolin Oxcarbazepine Cefixime Perampanel Cefotaxime Phenobarbital Cefradine Phenytoin Ceftaroline Pregabalin Ceftazidine Primidone Ceftriazone Retigabine Cefuroxime Rufinamide Chloramphenicol Sultiame Ciprofloxacin Tiagabine Clarithromycin Topiramate Clavulanic acid Valproate (Divalproex) Clindamycin Vigabatrin Cloxacillin Zonisamide Key to symbols Notes Further information is available at © Liverpool Drug Interactions Group, These drugs should not be coadministered www.hep-druginteractions.org University of Liverpool, Pharmacology Research Labs, Potential clinically significant interaction that is likely to require additional Predicted interactions are based on known 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF monitoring, alteration of drug dosage or timing of administration metabolic pathways and routes of clearance. We aim to ensure that information is accurate and consistent with current knowledge Potential interaction likely to be of weak intensity. Additional Caution is required in patients with hepatic and practice. However, the University of Liverpool and its servants or agents shall action/monitoring or dosage adjustment is unlikely to be required impairment as this may also increase drug levels not be responsible or in any way liable for the continued currency of information in and require dose modification. this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude No clinically significant interaction expected Where advice differs between countries, the liability for errors, omissions or inaccuracies to the fullest extent permitted by law. charts reflect the more cautious option. www.hep-druginteractions.org Interactions with PBC Agents Charts created August 2019. Full information available at www.hep-druginteractions.org Page 2 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Acid Acid Antihistamines Antivirals Cancer Therapies Astemizole Aciclovir Abiraterone Bilastine Amantadine Acalabrutinib Cetirizine Brivudine Anastrozole Chlorphenamine Cidofovir Avelumab Desloratadine Foscarnet Axitinib Diphenhydramine Oseltamivir Bevacizumab Doxylamine Blinatumomab Rimantadine Ebastine Valaciclovir Bortezomib Fexofenadine Zanamivir Bosutinib Hydroxyzine Brentuximab vedotin Anxiolytics/Hypnotics/Sedatives Levocetirizine Capecitabine Alprazolam Loratadine Carboplatin Promethazine Amobarbital Cetuximab Terfenadine Bromazepam for distribution. for Chlorambucil Antimigraine Agents Bromperidol Cisplatin Almotriptan Buspirone Daratumumab Dihydoergotamine Clobazam Dasatinib Eletriptan Clorazepate Doxorubicin Ergotamine Clotiapine Erlotinib Frovatriptan Diazepam Estramustine Methylergonovine Estazolam Etoposide Naratriptan Flurazepam Everolimus Pizotifen ersonal use only. Not for distribution. for only. Not use ersonal Lorazepam Exemestane Rizatriptan Lormetazepam Fludarabine Sumatriptan Midazolam (oral) Gefitinib Zolmiptriptan Midazolam (parenteral) Gemcitabine Antiprotozoals Oxazepam Idarubicin Amodiaquine Imatinib Artemether Quazepam Ipilimumab Artemisinin Temazepam Irinotecan Artesunate Triazolam Ixazomib Atovaquone Zaleplon Lapatinib Chloroquine Zolpidem Dihydroartemisinin Zopiclone Not only. use For personal for distribution. Letrozole Mercaptopurine Doxycycline Beta Blockers Methotrexate Halofantrine Atenolol Hydroxychloroquine Bisoprolol Mitoxantrone Lumefantrine Carvediol Nilotinib Mefloquine Celiprolol Niraparib Pentamidine Labetalol Nivolumab Primaquine Obinutuzumab nal use only. Not for distribution. For p for distribution. Not only. use nal Metoprolol Proguanil Nebivolol Ofatumumab Pyrimethamine Oxprenolol Olaratumab Quinine Pindolol Oxaliplatin r perso Sodium stibogluconate Propanolol Paclitaxel Sulfadoxine Sotalol Panitumumab Antipsychotics/Neuroleptics Timolol Pembrolizumab Amisulpride Bisphosphonates Rituximab Aripiprazole Alendronic acid Sorafenib Asenapine Clodronate Sunitinib Tamoxifen Chlorpromazine Ibandronic acid Chlorprothixene Temsirolimus Pamidronate Clozapine Vinblastine Risedronate Flupentixol Vincristine Fluphenazine Bronchodilators Vinorelbine Haloperidol Formoterol Contraceptives and Hormone Replacements Indacaterol Iloperidone Desogestrel Ipatropium bromide Levomepromazine Dienogest Montelukast Olanzapine Drospirenone Paliperidone Omalizumab Estradiol Perazine Salbutamol Ethinylestradiol Periciazine Salmeterol Etonogestrel (implant) Perphenazine Theophylline Etonogestrel (vaginal ring) Pimozide Tiotropium For personal use only. Not for distribution. Fo for distribution. Not only. use For personal Pipotiazine Not only. use For personal for distribution. only. Not use For personal Levonorgestrel (COC) Calcium Channel Blockers Prochlorperazine Levonorgestrel Amlodipine Quetiapine (Emergency Contraception) Risperidone Diltiazem Levonorgestrel (HRT) Sulpride Felodipine Levonorgestrel (implant) Thioridazine Nicardipine Levonorgestrel (IUD) Tiapride Nifedipine Levonorgestrel (POP) Trifluoperazine Nisoldipine Medroxyprogesterone (depot) Ziprasidone Nitrendipine Medroxyprogesterone (oral) Zuclopentixol Verapamil Norethisterone (norethindrone) Key to symbols Notes Further information is
Recommended publications
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name

    SPIRONOLACTONE Spironolactone – Oral (Common Brand Name

    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
  • Table 2. 2012 AGS Beers Criteria for Potentially

    Table 2. 2012 AGS Beers Criteria for Potentially

    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
  • Dofetilide (Tikosyn): a New Drug to Control Atrial Fibrillation

    Dofetilide (Tikosyn): a New Drug to Control Atrial Fibrillation

    CURRENT DRUG THERAPY WALID I. SALIBA, MD Section of Cardiac Electrophysiology and Pacing, CREDIT Department of Cardiology, Cleveland Clinic Dofetilide (Tikosyn): A new drug to control atrial fibrillation ABSTRACT OFETILIDE (Tikosyn), a new antiarrhyth- mic drug, can convert atrial fibrillation Dofetilide, a new class III antiarrhythmic agent, selectively and atrial flutter to sinus rhythm in approxi- blocks a specific cardiac potassium channel, lKr, increasing mately 30% of cases and maintain sinus the effective refractory period of the myocyte and thereby rhythm after electrical or pharmacologic con- terminating reentrant arrhythmias. Given orally, it appears version for up to 1 year in 60% to 70% of to effectively convert atrial fibrillation and atrial flutter to cases, without increasing the risk of sudden sinus rhythm and maintain sinus rhythm after conversion in death in patients at high risk. appropriately selected patients. This paper reviews the Such new drugs are needed, as many of the pharmacology of dofetilide, the evidence of its antiarrhythmic drugs in use up to now have effectiveness, and the appropriate precautions in using it. actually produced higher mortality rates in clinical trials than did placebo, or cause unac- ceptable side effects. KEY POINTS This article reviews the mechanism of action, safety, effectiveness, and clinical use of Dofetilide is generally well tolerated but like other class III dofetilide. drugs can cause torsades de pointes. The risk is dose- dependent and can be minimized by adjusting the dosage • PROBLEMS WITH PREVIOUS DRUGS according to creatinine clearance and QT interval, by excluding patients with known risk factors for long QT A variety of drugs have been used to terminate syndrome and torsades de pointes, and by starting or prevent atrial and ventricular arrhythmias, treatment in an inpatient monitored setting for the first 3 but their safety, efficacy, and tolerability in days.
  • Safety and Efficacy of Dronedarone from Clinical Trials to Real

    Safety and Efficacy of Dronedarone from Clinical Trials to Real

    Europace (2019) 21, 1764–1775 REVIEW doi:10.1093/europace/euz193 Safety and efficacy of dronedarone from clinical Downloaded from https://academic.oup.com/europace/article-abstract/21/12/1764/5536329 by Uppsala Universitetsbibliotek user on 20 February 2020 trials to real-world evidence: implications for its use in atrial fibrillation Giuseppe Boriani1, Carina Blomstro¨m-Lundqvist2, Stefan H. Hohnloser3, Lennart Bergfeldt4,5, Giovanni L. Botto6, Alessandro Capucci7, Ignacio Ferna´ndez Lozano8, Andreas Goette9,10, Carsten W. Israel3,11, Jose´ L. Merino12, and A. John Camm13* 1Division of Cardiology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy; 2Department of Medical Science and Cardiology, Uppsala University, Uppsala, Sweden; 3Division of Clinical Electrophysiology, Department of Cardiology, J W Goethe University, Frankfurt, Germany; 4Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 5Va¨stra Go¨taland, Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; 6ASST Rhodense, Ospedale di Circolo Rho, Milan, Italy; 7Universita` Politecnica delle Marche, Ancona, Italy; 8Sociedad Espanola~ de Cardiologı´a, Madrid, Spain; 9Medical Clinic II, Cardiology Department, St Vincenz-Krankenhaus Paderborn, Paderborn, Germany; 10Working Group Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg, Germany; 11Clinic of Internal Medicine, Bethel-Clinic, Bielefeld, Germany; 12Arrhythmia & Robotic EP Unit, Hospital Universitario La Paz-IdiPaz, Madrid, Spain; and 13Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, St George’s University of London, Cranmer Terrace, London SW17 0RE, UK Received 17 May 2019; editorial decision 13 June 2019; accepted 20 June 2019; online publish-ahead-of-print 19 July 2019 Efficacy and safety of dronedarone was shown in the ATHENA trial for paroxysmal or persistent atrial fibrillation (AF) patients.
  • Acebutolol Hydrochloride Eq 200 Mg Base, Capsule, Oral, 100 0.4612 B Eq 400 Mg Base, Capsule, Oral, 100 0.6713 B

    Acebutolol Hydrochloride Eq 200 Mg Base, Capsule, Oral, 100 0.4612 B Eq 400 Mg Base, Capsule, Oral, 100 0.6713 B

    TRANSMITTAL NO. 37 - FEDERAL UPPER LIMIT DRUG LIST NOVEMBER 20, 2001 The following list of multiple source drugs meets the criteria set forth in 42 CFR 447.332 and Section 1927(e) of the Social Security Act, as amended by OBRA 1993. Payment for multiple source drugs identified and listed below must not exceed, in the aggregate, payment levels determined by applying to each drug entity a reasonable dispensing fee (established by the State and specified in the State plan), plus an amount based on the limit per unit which CMS has determined to be equal to 150 percent applied to the lowest price listed (in package sizes of 100 units, unless otherwise noted) in any of the published compendia of cost information of drugs. The listing is based on data current as of April 2001 from First Data Bank (Blue Book), Medi- Span, and the Red Book. This list does not reference the commonly known brand names. However, the brand names are included in the electronic FUL listing provided to the state agencies. The FUL price list and electronic listing are available at http://www.cms.hhs.gov/Reimbursement/05_FederalUpperLimits.asp. In accordance with current policy, Federal financial participation will not be provided for any drug on the FUL listing for which the FDA has issued a notice of an opportunity for a hearing as a result of the Drug Efficacy Study and Implementation (DESI) program, and which has been found to be a less than effective or is identical, related or similar (IRS) to the DESI drug. The DESI drug is identified by the Food and Drug Administration or reported by the drug manufacturer for purposes of the Medicaid drug rebate program.
  • Understanding Benzodiazephine Use, Abuse, and Detection

    Understanding Benzodiazephine Use, Abuse, and Detection

    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
  • Clinical Rx Forum Volume 4 Issue 1

    Clinical Rx Forum Volume 4 Issue 1

    In This Issue Clevidipine for Hypertensive Urgency and Emergency From the Department of Pharmacy Tramadol: No Longer the Codeine Alternative January/February Issue 2016 Volume 4, Issue 1 FDA Medication Safety Alert: Risk of VTE with TestClevidipine for Hypertensive Urgency and Emergency osterone By: Gretchen D’Arcangelo, Pharm.D. Marcia J. Wyman, Pharm.D., BCPS Introduction: Hypertensive emergen- istration (FDA) for the reduction of BP Drug Information Pharmacist cies are deLined by potentially life- when oral therapy is not feasible Editor threatening elevations in blood pres- or desirable. 3 sure (BP) greater than 180/120 mmHg Mandy C. Leonard, Pharm.D., BCPS Pharmacokinetics: Following IV ad- System Director, Drug Use Policy and and are also paired with organ dysfunc- 1 ministration, clevidipine is rapidly me- Formulary Management tion. Hypertensive urgencies, on the Editor other hand, do not have the characteris- tabolized by blood and tissue esterases tic organ dysfunction present. These giving it a very quick onset of action Meghan K. Lehmann, Pharm.D., BCPS hypertensive crises are said to account and short half-life. 3 Its pharmacologic Drug Information Specialist effect starts within 2 to 4 minutes with Editor for up to 3% of emergency department admissions, with about three-fourths of a duration of action of up to 15 minutes. Marigel Constantiner, MSc, BCPS, CGP, CPh those admissions due to hypertensive EfLicacy and Safety: Patients undergo- Drug Information Specialist emergencies. 2 In patients with either Associate Editor ing cardiac surgery diagnosed with hy- hypertensive urgency or emergency, pertension in the past 6 months were immediate BP reduction should be at- Christopher Snyder, B.S., R.Ph.
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
  • Pharmaceutical Compositions of Clevidipine and Methods

    Pharmaceutical Compositions of Clevidipine and Methods

    (19) TZZ ¥ ZZ_T (11) EP 2 320 740 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61P 9/12 (2006.01) A61K 31/519 (2006.01) 26.03.2014 Bulletin 2014/13 A61K 9/10 (2006.01) (21) Application number: 09803550.4 (86) International application number: PCT/US2009/052127 (22) Date of filing: 29.07.2009 (87) International publication number: WO 2010/014727 (04.02.2010 Gazette 2010/05) (54) PHARMACEUTICAL COMPOSITIONS OF CLEVIDIPINE AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS OF THE SAME PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON CLIVIDIPINE UND VERFAHREN ZUR HERSTELLUNG VON KONZENTRATIONEN DARAUS MIT GERINGEM VERUNREINIGUNGSGRAD COMPOSITIONS PHARMACEUTIQUES, COMPRENANT CLIVIDIPINE ET PROCÉDÉS POUR PRODUIRE DE FAIBLES CONCENTRATIONS D’IMPURETÉ DE CELLES-CI (84) Designated Contracting States: • FLOOD Keith AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cary, NC 27518 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • RAMAKRISHNA Kornepati PT RO SE SI SK SM TR Cary, NC 27513 (US) (30) Priority: 03.09.2008 US 93772 P (74) Representative: Wallace, Sheila Jane et al 01.08.2008 US 85597 P Marks & Clerk LLP 90 Long Acre (43) Date of publication of application: London 18.05.2011 Bulletin 2011/20 WC2E 9RA (GB) (60) Divisional application: (56) References cited: 14150954.7 WO-A1-00/31035 WO-A1-2006/118210 US-A1- 2003 119 883 US-A1- 2005 272 763 (73) Proprietors: US-A1- 2005 276 824 US-A1- 2006 047 125 • The Medicines Company US-A1- 2007 196 465 US-A1- 2008 019 978 Parsippany, NJ 07054 (US) • Hospira, Inc.
  • Exforge HCT in Patients with These Highlights Do Not Include All the Information Needed to Use Diabetes (4) EXFORGE HCT Safely and Effectively

    Exforge HCT in Patients with These Highlights Do Not Include All the Information Needed to Use Diabetes (4) EXFORGE HCT Safely and Effectively

    HIGHLIGHTS OF PRESCRIBING INFORMATION Do not coadminister aliskiren with Exforge HCT in patients with These highlights do not include all the information needed to use diabetes (4) EXFORGE HCT safely and effectively. See full prescribing information for EXFORGE HCT. -----------------------WARNINGS AND PRECAUTIONS ----------------------- Hypotension: Correct volume depletion prior to initiation (5.2) ® EXFORGE HCT (amlodipine, valsartan, and hydrochlorothiazide) Increased angina and/or myocardial infarction (5.3) tablets, for oral use Monitor renal function and potassium in susceptible patients (5.4, 5.5) Initial U.S. Approval: 2009 Exacerbation or activation of systemic lupus erythematosus (5.7) WARNING: FETAL TOXICITY Observe for signs of fluid or electrolyte imbalance (5.9) See full prescribing information for complete boxed warning. Acute angle-closure glaucoma (5.10) When pregnancy is detected, discontinue Exforge HCT as soon as possible. (5.1) ------------------------------ADVERSE REACTIONS ------------------------------ Drugs that act directly on the renin-angiotensin system can cause Most common adverse events (≥ 2% incidence) are dizziness, peripheral injury and death to the developing fetus. (5.1) edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea, and nasopharyngitis. (6.1) ---------------------------INDICATIONS AND USAGE --------------------------- Exforge HCT is a combination tablet of amlodipine, a dihydropyridine To report SUSPECTED ADVERSE REACTIONS, contact Novartis calcium channel blocker (DHP CCB), valsartan, an angiotensin II receptor Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA- blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Exforge HCT is 1088 or www.fda.gov/medwatch. indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, ------------------------------DRUG INTERACTIONS ------------------------------ primarily strokes, and myocardial infarctions.
  • Therapeutic Class Overview Beta-Adrenergic Blocking Agents

    Therapeutic Class Overview Beta-Adrenergic Blocking Agents

    Therapeutic Class Overview Beta-adrenergic Blocking Agents INTRODUCTION Approximately 92.1 million American adults have at least 1 type of cardiovascular disease according to the American Heart Association (AHA) Heart Disease and Stroke Statistics 2018 update. From 2003 to 2015, mortality associated with cardiovascular disease declined 25.5% (Benjamin et al 2018). Beta-adrenergic blocking agents (beta-blockers) are a group of drugs that block the sympathomimetic effects of catecholamines on beta receptors. This results in negative inotropic and chronotropic effects and relaxation of smooth muscle. Beta-blockers have varied pharmacologic properties. ○ Cardioselective beta-blockers preferentially interact with beta1-receptors, which are predominantly found in the heart. Non-cardioselective beta-blockers also interact with beta2-receptors found on smooth muscle in the lungs, blood vessels, and other tissues. The cardioselectivity of beta-blockers is dose dependent; therefore, beta2 blockade can occur at higher doses with certain cardioselective agents. ○ Some beta-blockers (acebutolol and pindolol) have intrinsic sympathomimetic activity (ISA), which may result in a lower incidence of bradycardia and bronchoconstriction (Facts and Comparisons 2018). In addition, some beta- blockers (nebivolol and propranolol) have higher lipophilicity, which may increase the risk for central nervous system- related adverse events (Facts and Comparisons 2018). ○ Carvedilol and labetalol also block alpha-adrenergic receptors and may reduce peripheral resistance more than other beta-blockers (Clinical Pharmacology 2018). Specific indications for the beta-blockers vary by product. Most beta-blockers (all except sotalol) are approved to treat hypertension (HTN). The 2017 American College of Cardiology (ACC)/AHA clinical practice guideline defines HTN as blood pressure (BP) ≥ 130/80 mm Hg (Whelton et al 2017).
  • A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

    A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

    Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 RESEARCH ARTICLE A Drug Repositioning Approach Identifi es Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors Nadine S. Jahchan 1 , 2 , Joel T. Dudley 1 , Pawel K. Mazur 1 , 2 , Natasha Flores 1 , 2 , Dian Yang 1 , 2 , Alec Palmerton 1 , 2 , Anne-Flore Zmoos 1 , 2 , Dedeepya Vaka 1 , 2 , Kim Q.T. Tran 1 , 2 , Margaret Zhou 1 , 2 , Karolina Krasinska 3 , Jonathan W. Riess 4 , Joel W. Neal 5 , Purvesh Khatri 1 , 2 , Kwon S. Park 1 , 2 , Atul J. Butte 1 , 2 , and Julien Sage 1 , 2 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 ABSTRACT Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformat- ics approach querying a large compendium of gene expression profi les to identify candidate U.S. Food and Drug Administration (FDA)–approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endog- enous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein–coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma.